Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01766050 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT01766050 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 45 participants.
The verdict
NCT01766050, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam
Interventions
- DRUG Midazolam
- DRUG Losartan
- DRUG Omeprazole
- DRUG Caffeine
- DRUG Dextromethorphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01766050
The ClinicalTrials.gov registry entry for NCT01766050 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT01766050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01766050 about?
NCT01766050 is a clinical study titled "Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers". The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam
What is the current status of trial NCT01766050?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2013-01. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01766050?
The interventions under investigation include: Midazolam (DRUG), Losartan (DRUG), Omeprazole (DRUG), Caffeine (DRUG), Dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT01766050?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.